ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma

The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
On location

CRISPR Gene Editing May Offer Curative Potential for Sickle Cell Disease

CRISPR-based gene editing techniques may offer curative potential for sickle cell disease (SCD) when used to target Krüppel-like factor 1 (KLF1) mutations, according to...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia

Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
On location

BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma

In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
On location

Avatrombopag Demonstrates Efficacy in ITP, Regardless of Prior Treatment

Treatment with the thrombopoietin receptor agonist (TPO-RA) avatrombopag led to durable platelet count responses in patients with immune thrombocytopenia (ITP), with responses among both...
On location

Big Ideas on Burnout: Trainees Propose System-Wide Solutions

The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...
Advertisement

Current Issue

Mid-January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.

Block title